Introduction
Gene therapy is expected to become a promising therapeutic method for treating and modulating a diverse array of diseases.
1 Two-thirds of the large number of gene therapy clinical trials that have been or are being conducted worldwide are for cancer. 2, 3 Gene therapy offers a potentially useful approach for highly selective, curative treatment of cancers, because a variety of genes controlling the molecular processes can be introduced by gene transfer. 4 A variety of gene therapy techniques for cancer, such as oncogene inactivation, tumor suppressor gene replacement, inhibition of angiogenesis and transfer of drug resistance genes, have been developed. Among these strategies, transfection of tumor suppression genes into cancer cells has been considered as a promising tool for arresting cell growth and inducing apoptosis. 5 To date, studies report that a variety of tumor suppression genes, such as p53, 6, 7 Rb, 8 and PTEN, 9 have been successfully applied in cancer gene therapy.
Programmed cell death 4 (Pdcd4) as a tumor suppressor gene inhibits neoplastic transformation and tumor invasion. Pdcd4 directly inhibits the helicase activity of eukaryotic initiation factor-4A, subsequently inhibiting cap-dependent translation.
10 PDCD4 seems to be the first example of a protein in mammalian cells that inhibits translation by attenuation of eukaryotic initiation factor-4A activity. 11 Although the molecular mechanism of PDCD4 0 s action is not completely clear, much evidence indicates that downregulation of PDCD4 expression correlates with tumor cell progression. 12, 13 Recent studies indicate that expression of PDCD4 in breast cancer cells, 14 lungs of K-ras null mice 15 and in the transgenic mouse model of skin carcinogenesis 11 induced apoptosis and prevented tumorigenesis and tumor progression. In addition, downregulation of PDCD4 expression using Pdcd4 short hairpin RNA was sufficient to promote tumor progression and alter cell morphology in HT29 colon tumor cells. 12 Therefore, delivery and expression of the Pdcd4 gene in cancer can be an effective approach for cancer therapy.
In a previous study, we prepared folate-PEG-baculovirus containing the luciferase reporter gene to increase the stability and specificity for tumortargeting. 16 The luciferase reporter gene showed enhanced transduction efficiency and tumor-targeting ability. In this study, to investigate whether expression of the Pdcd4 gene prevents or inhibits tumorigenesis both in vitro and in vivo, F-PBac-Pdcd4 was prepared and delivered into cells from the human epidermal carcinoma (KB) cell line for testing in vitro, and injected into tumors in tumor xenograft model mice for testing in vivo. Subsequently, reduction of tumor size and the expression level of representative apoptosis signals in xenograft model mice were evaluated.
Materials and methods

Materials
A hetero-bi-functional poly(ethylene glycol) derivative (NH 2 -PEG-COOH, MW 5000) and methoxy poly(ethylene glycol) succinimidyl succinate (mPEG-SS, MW 5000) were obtained from NOF Cooperation (Tokyo, Japan) and Sunbio Cooperation (Seoul, Korea), respectively. Dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS) and dimethylsulfoxide were purchased from Sigma-Aldrich (St Louis, MO). Bcl2-associated X protein (BAX), Bcl-associated death promoter, Bcl-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies for western blot were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). b-Actin antibody for western blot was purchased from Abcam (Cambridge Science Park, UK). Monoclonal PDCD4 antibody was produced using a general method described elsewhere.
Synthesis of F-PEG conjugate F-PEG conjugate was synthesized as previously reported. 16 Briefly, dicyclohexylcarbodiimide and Nhydroxysuccinimide were added to folate dissolved in dimethylsulfoxide at a molar ratio of 2:2:1 to activate the carboxyl groups of folate and stirred for 18 h under nitrogen atmosphere. Activated folate dissolved in dimethylsulfoxide was mixed with NH 2 -PEG-COOH, MW 5000 at a molar ratio of 4:1 (Folate:PEG) and stirred for 4 h under nitrogen atmosphere. To remove the unreacted folate, the F-PEG conjugate was dialyzed (Spectra/Por, MW cutoff 3500) for 3 days against dimethylsulfoxide and for an additional 2 days against distilled water, and subsequently freeze-dried. The degree of conjugation of folate was estimated by measuring 1 H nuclear magnetic resonance (Avance 600, Bruker, Germany).
To introduce F-PEG onto the baculovirus, the carboxyl group of the F-PEG conjugate was activated following the same method as described above. Activated F-PEG was stored at À20 1C.
Introduction of F-PEG or PEG onto baculovirus F-PEG or PEG was introduced onto the baculovirus as previously reported. 17 Briefly, the baculovirus was concentrated to the desired pfu per volume from cell culture medium by centrifugation (15 000 r.p.m, 30 min at 4 1C). The conjugation reaction was performed between various concentrations of F-PEG or mPEG-SS and concentrated baculovirus in phosphate buffered saline (PBS) solution at 4 1C for 2 days with gentle rotation. After the reaction, the unreacted F-PEG or mPEG-SS was removed by centrifugation (15 000 r.p.m, 30 min at 4 1C). Subsequently, F-P-Bac-Pdcd4 and P-Bac-Pdcd4 were prepared after resuspension by adding the PBS into sedimented baculovirus pellets.
Cell lines and cell culture KB cells were cultured in RPMI 1640 (Gibco BRL, Paris, France). Two weeks before transduction, culture media for the KB cells was changed to folate-free RPMI 1640 (Gibco BRL, cat. 27016) to induce overexpression of folate receptors (FRs) on KB cell membranes. Each cell culture medium was supplemented with 10% fetal bovine serum, streptomycin at 100 mg ml À1 and penicillin at 100 U ml
À1
. All cells were incubated at 37 1C in a humidified 5% CO 2 atmosphere.
Transduction studies KB cells were incubated with folate-free RPMI 1640 medium for 2 weeks before the experiment, and transduction efficiency in FR overexpressed KB cells was compared with that in normal KB cells cultured in folate-enriched (1 mg l
) RPMI 1640 medium. KB cells were seeded at an initial density of 5 Â 10 5 or 1.5 Â 10 5 cells per well in 6-or 24-well plates, respectively, depending on subsequent experiments. After 18 h of incubation, F-P-Bac-Pdcd4 were added into plates at a multiplicity of infection of 150, 300 or 500 and incubated for 1 h. Growth media was replaced by fresh media containing 10% serum and 10 mM sodium butyrate (a histone deacetylase inhibitor) and cells were incubated for 24 h.
MTT assay KB cells were seeded in 24-well plates and transduced by F-P-Bac-Pdcd4 at a multiplicity of infection of 150, 300 and 500. To compare the effect of Pdcd4 gene on cell viability, Bac or F-P-Bac-EGFP were transduced into KB cells as controls. After 3 h of incubation with 0.5 mg per ml of MTT solution, media was aspirated and dimethylsulfoxide was added to dissolve the formazan product. The mitochondrial activity of the cells was measured at 540 nm by an ELISA plate reader (GLR 1000, Genelabs Diagnostics, Singapore). Cell viability (%) was calculated according to the following equation: cell viability (%) ¼ [OD 540 (sample)/OD 540 (control)] Â 100.
Apoptosis and necrosis measurement
Apoptosis and necrosis induced by F-P-Bac-Pdcd4 were measured by the Annexin V-FITC assay. KB cells were seeded in six-well plates and transduced by F-P-BacPdcd4 at a multiplicity of infection of 300. After 24 h of expression, transduced cells (1 Â 10 5 cells per sample) were harvested and stained with Annexin V-FITC and propidium iodide using the Annexin V-FITC kit (Abcam, Cambridge Science Park, UK) according to the manufacturer's instructions. Cell apoptosis and necrosis were measured by FACS Calibur System (BD Biosciences Clontech, San Jose, CA). The percent of cells undergoing apoptosis or necrosis after transduction with Bac-Pdcd4, P-Bac-Pdcd4 and F-P-Bac-Pdcd4 was determined after normalizing by the Bac-EGFP, P-Bac-EFGP and F-PBac-EGFP, respectively. The experiments were performed in triplicate and 10 000 cells were counted in each experiment.
Western blot analysis
The expression levels of various proteins related to apoptosis were detected by western blot analysis both in vitro and in vivo. For in vitro study, KB cells were seeded in six-well plates and transduced by F-P-Bac-Pdcd4 at a multiplicity of infection of 300. After 24 h of expression, cells were lysed and protein was extracted. For in vivo study, xenograft model mice established by subcutaneous implantation of KB cells (1 Â 10 6 cells) were injected into the recombinant baculovirus (1 Â 10 8 p.f.u.) when the tumors grew to a size of approximately 130 mm 3 . After 4 weeks of administration of recombinant baculovirus, tumors of xenograft model mice were collected and homogenized for extraction of protein. Total protein from KB cells or tumors was quantified using a Bradford assay kit (Bio-Rad, Hercules, CA). Equal amounts of protein sample were separated on sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked for 1 h in Tris-buffered saline þ Tween 20 containing 5% skim milk. Immunoblotting was performed by incubating the membranes overnight with their corresponding primary antibodies at 4 1C. After washing in Tris-buffered saline þ Tween 20, the membranes were incubated with a horseradish peroxidase (HRP)-labeled secondary antibody (Zymed, Carlsbad, CA) and the bands of interest were detected using a luminescent image analyzer, LAS-3000 (Fujifilm, Japan). Results were quantified using the Multi Gauge version 2.02 program of the LAS-3000.
Tumor xenograft study Athymic (BALB/c, nu/nu, 5-weeks old) male, nude mice were obtained from SLC (Hamamatsu, Japan). The mice were housed in autoclaved plastic filter-top cages, maintained in a laboratory animal facility (23 ± 2 1C, 50±20% relative humidity, 12 h light/dark cycle), and acclimatized for at least 1 week before the beginning of the study. The mice were fed with a folate-free rodent diet (Cat. no. 518826, Dyets, Bethlehem, PA) for 2 weeks before tumor inoculation. All animal experiments were performed in accordance with the guidelines of Seoul National University for the care and use of animals. Xenografts were established from the KB cell lines by the subcutaneous implantation of 1 Â 10 6 cells in serum-free media into the flank of each animal. 18 The tumor volume was calculated using the formula
, where a and b are the largest and smallest tumor diameters measured using a caliper, respectively. The recombinant baculovirus (1 Â 10 8 p.f.u.) was administered when the tumors grew to a size of approximately 130 mm 3 . Tumor volume was measured twice weekly for 4 weeks. Both the control group (PBS) and baculovirus groups (P-Bac-Pdcd4, F-P-Bac-Pdcd4) were treated with intratumoral injections every 3 days during the experiment.
Statistical analysis
Statistical analysis was performed using Student's t-test (GraphPad Software, San Diego, CA). All results are given as the mean ± s.d. Statistical significance was represented by * for P-values o0.05 and ** for P-values o0.01.
Results
Synthesis and characterization of F-PEG and F-P-Bac-Pdcd4
The F-PEG conjugate was successfully synthesized through an amide linkage between the carboxyl group of folate and the primary amine one of a hetero-bifunctional PEG derivative as previously reported. 16 The resultant F-PEG conjugate was analyzed by 1 H nuclear magnetic resonance. Folate content in the conjugate was about 70 mol%. PEG or F-PEG conjugates were introduced onto the baculovirus surface by amide linkage between the carboxyl group of PEG or F-PEG and the amine one of the baculovirus ( Figure 1 ). As previously reported, the degree of introduction of PEG or F-PEG onto the baculovirus surface was increased by increasing PEG or F-PEG concentration in the coupling reaction and introduction of PEG or F-PEG showed less negative surface charge because of the hydrophilic PEG chain. 16 
Cell viability
The cytotoxicity of baculovirus containing Pdcd4 genes was evaluated by MTT assay. As shown in Figure 2 , cell viability decreased to 30% of control when cells were treated with F-P-Bac-Pdcd4, whereas approximately 90% cell viability was observed when cells were treated with wild-type baculovirus (Bac) or the F-P-Bac-containing EGFP gene (F-P-Bac-EGFP). Moreover, cell viability was dependent on the multiplicity of infection and the concentration of F-PEG used in the reaction when treated with F-P-Bac-Pdcd4. In contrast to F-P-Bac-Pdcd4, approximately 80 or 70% cell viability was observed for baculovirus containing the Pdcd4 gene (Bac-Pdcd4) or PEG-baculovirus containing the Pdcd4 gene (P-BacPdcd4), respectively. In particular, cell viability increased with the concentration of PEG used in the reaction for cells treated with P-Bac-Pdcd4. Based on these results, all further in vitro studies were performed using recombinant baculoviruses reacted with 3 mg per ml PEG or F-PEG for P-Bac-Pdcd4 or F-P-Bac-Pdcd4, respectively, at a multiplicity of infection of 300 and expressed for 24 h.
Receptor-mediated endocytosis studies
To confirm whether the high cytotoxicity of F-P-BacPdcd4 was a result of delivering and expressing the Pdcd4 gene through FR-mediated transduction, the transduction efficiency of each carrier was evaluated by measuring the expression levels of the Pdcd4 gene in the folate-enriched regular or folate-free RPMI 1640 medium. As shown in Figure 3 , the PDCD4 protein expression level of the F-PBac-Pdcd4 in the folate-free medium was significantly higher than that of the Bac, F-P-Bac-EGFP, Bac-Pdcd4 and P-Bac-Pdcd4. The PDCD4 protein expression level of F-P-Bac-Pdcd4 was highly inhibited in the folate-enriched regular medium, whereas there was little difference in the PDCD4 protein expression levels of Bac-Pdcd4 or P-BacPdcd4 between folate-enriched regular and folate-free medium. In addition, Bac and F-P-Bac-EGFP used as controls hardly expressed the PDCD4 protein in both cells ( Figure 3 ) and the expression level of these was similar to that of cells without transduction (data not shown). These results indicated that F-P-Bac-Pdcd4 efficiently transduced through FR-mediated endocytosis and expression of PDCD4 protein had a direct effect on the cytotoxicity. Because Bac and F-P-Bac-EGFP had little cytotoxicity ( Figure 2 ) and rarely expressed the PDCD4 protein (Figure 3 ), the effect on apoptosis after transduction of F-P-Bac-Pdcd4 was only compared with Bac-Pdcd4 and P-Bac-Pdcd4 (the control in Figures 4 and 5 means only cells without transduction).
Cell apoptosis and necrosis
To investigate whether expression of PDCD4 induces apoptosis and/or necrosis, fluorescence-activated cell sorter analysis was performed by Annexin V-FITC and propidium iodide staining. The percent of cells undergoing apoptosis in the F-P-Bac-Pdcd4-transduced samples (approximately 15%) was twofold and fourfold higher than in the P-Bac-Pdcd4 (approximately 7%) and Bac-Pdcd4-transduced samples (approximately 3.5%), respectively ( Figure 4 ). On the other hand, necrotic cell death was approximately 9% in all three groups because all groups used a baculovirus-based carrier. Together, F-P-Bac-Pdcd4 efficiently delivered the Pdcd4 gene and expressed more PDCD4 protein, subsequently inducing more apoptosis than P-Bac-Pdcd4 and Bac-Pdcd4.
Analysis of protein expression level in vitro
The expression of various proteins involved in apoptosis signaling was measured by Western blot after transduction with F-P-Bac-Pdcd4. As shown in Figure 5 , the expression levels of pro-apoptotic proteins such as Bcl2-associated death promoter and Bcl2-associated X protein (BAX) in the F-P-Bac-Pdcd4-treated group were much higher than in the Bac-Pdcd4-treated group. The P-Bac-Pdcd4-treated group had a higher expression level of BAX protein than in the Bac-Pdcd4 treated groups, whereas it showed less BAX expression than the F-P-Bac-Pdcd4-treated group. In contrast, the F-P-Bac-Pdcd4-treated group had the lowest level of anti-apoptotic Bcl-2 protein among the groups.
Profile of tumor growth in the tumor xenograft model To validate our in vitro results, we performed xenograft experiments by treatment with recombinant baculovirus in animal models. KB oral squamous carcinoma cells were implanted subcutaneously in athymic mice. In a preliminary study, we injected the PBS (control), Bac, Bac-Pdcd4, P-Bac-Pdcd4 and F-P-Bac-Pdcd4 every 7 days with four mice in each group and evaluated the profile of tumor growth. Whereas the injection of F-P-Bac-Pdcd4 and P-Bac-Pdcd4 caused reduction in tumor volume, Bacand Bac-Pdcd4-treated groups had little effect on tumor volume reduction as compared with the control group (data not shown). Therefore, all further in vivo studies were performed after injection of PBS, P-Bac-Pdcd4 and F-P-Bac-Pdcd4 in animal models (the control in Figures 6 and 7 means the PBS-injected group). As shown in Figure 6 , the administration of F-P-Bac-Pdcd4 caused a 54% reduction in tumor size as compared with the tumor volume of the control, whereas P-Bac-Pdcd4 administration caused a 27% reduction in tumor size as compared with the tumor volume of the control. The growth delay was calculated as the number of days required to reach a tumor volume of 1000 mm 3 for treatment groups minus the number of days required for the control to reach the same volume. As shown in Figure 6 , F-P-Bac-Pdcd4 administration delayed tumor growth by approximately 7 and 10 days as compared with P-Bac-Pdcd4 and control, respectively.
Analysis of protein expression level in vivo
We used western blot to measure the expression of various pro-and anti-apoptotic proteins in the mouse tumors after injection with F-P-Bac-Pdcd4. The results were similar to those obtained in vitro. The expression of PDCD4 protein in the F-P-Bac-Pdcd4-treated group was significantly higher than in the control and P-Bac-Pdcd4-treated groups, as shown in Figures 7a and b . The P-BacPdcd4-treated group also had a higher expression level of PDCD4 protein than that of the control group. F-P-BacPdcd4-injected tumors showed a significant increase in pro-apoptotic proteins such as Bcl-associated death promoter and BAX (Figures 7c and d) . In addition, expression of the anti-apoptotic protein Bcl-2 was significantly lower in F-P-Bac-Pdcd4-injected tumors than in the P-Bac-Pdcd4-injected tumors.
Discussion
Current virus-based carriers have potential for both gene delivery and expression, and viral vector systems are a well-studied strategy for cancer gene therapy. 19 A variety of animal viruses, such as adenoviruses, 20 adeno-associated virus , 4 retroviruses 21 and herpes simplex viruses, 22 have been used as gene carriers for cancer treatment. However, several hurdles that prevent the safe use of animal virus vectors in gene therapy remain, including immunogenicity, lack of specificity and the potential for insertional mutagenesis inducing oncogenesis. 23 In contrast, baculovirus containing an appropriate eukaryotic promoter is considered to be an attractive candidate for gene therapy applications because of its ability to transfer Figure 7 Expression levels of PDCD4 and apoptotic related proteins injected with F-P-Bac-Pdcd4 in the tumor. Lysates from the tumor injected with P-Bac-Pdcd4 and F-P-Bac-Pdcd4 were analyzed for (a) PDCD4 protein expression and (c) apoptotic related proteins (Bcl-associated death promoter (BAD), Bcl2-associated X protein (BAX) and Bcl-2) expression by Western blot (I: control; II: P-Bac-Pdcd4; and III: F-P-Bac-Pdcd4). and express target genes efficiently both in vitro and in vivo. 24 The lack of toxicity in mammalian cells is one of the chief merits of baculovirus as a gene carrier. 25 However, baculovirus must be modified to achieve specificity for target delivery to the desired cells or tissues. An elegant method to obtain efficiency and specificity is the improvement of the surface characteristics of the baculovirus by introducing specific ligands or moieties through genetic or chemical modification. 26 In a previous study, to improve the surface characteristics of the baculovirus and help it to target FRs on the membranes of tumor cells, F-PEG conjugate was introduced onto its surface by chemical modification. 16 Our previous results showed that the improvement of surface properties after introduction of F-PEG onto the baculovirus enhanced the transduction efficiency, indicating that the surface characteristics of gene carriers are an important parameter for efficient gene delivery. KB cells, which are broadly used as FR-positive cells, overexpressed the FRs on their membranes, 27, 28 and were used in transduction experiments and competition assay for confirming the receptormediated delivery of F-P-Bac. These results indicated that attachment of folate as a tumor-targeting ligand made F-P-Bac a tumor-specific gene carrier. Therefore, this study showed that F-P-Bac had potential as an efficient delivery vehicle for tumor targeting. 16 In this study, we attempted to induce apoptosis by delivering F-P-BacPdcd4 into FR-positive KB cells and tumor xenograft model mice.
Minimal cytotoxicity is an important prerequisite for a gene therapy vector. To test the cytotoxicity of baculovirus, we used the MTT assay. The low cytotoxicity of Bac (Figure 2 ) is consistent with previous reports that the cytotoxicity of baculovirus in mammalian cells appears to be comparatively low owing to the high species specificity of the baculovirus and lack of replication in mammalian cells. 29 Moreover, F-P-Bac-EGFP, similar to Bac's low cytotoxicity indicating that the chemical modification of baculovirus with F-PEG had little effect on cytotoxicity and the cytotoxicity of baculovirus was not a barrier to its use in therapeutic applications. As wild-type and chemically modified baculovirus as gene carriers had a low cytotoxicity in KB cells, we hypothesized that the high cytotoxicity of F-P-Bac-Pdcd4 could be the result of delivery and expression of the Pdcd4 gene. As expected, our hypothesis was confirmed when we observed the high expression level of PDCD4 protein of F-P-Bac-Pdcd4 in the folate-free medium (Figure 3) . However, F-P-BacPdcd4 still expressed the PDCD4 protein in the folateenriched medium, indicating that F-P-Bac still entered into KB cells through non-specific endocytosis 30 as well as receptor-mediated endocytosis (Figure 3) . Moreover, PDCD4 protein was expressed by transduction of BacPdcd4 and P-Bac-Pdcd4 in the folate-free and enriched media because of non-specific endocytosis of baculovirus itself. However, there was no statistical difference in the PDCD4 expression after treatment of Bac-Pdcd4 and P-Bac-Pdcd4 in both the media, whereas expression level of PDCD4 was highly inhibited after transduction of F-PBac-Pdcd4 in folate-enriched medium (Figure 3b) . Together, the MTT and Western blot assays showed that PDCD4 protein was efficiently expressed after transduction with F-P-Bac-Pdcd4 through receptor-mediated endocytosis, subsequently causing high cytotoxicity in KB cells.
To confirm whether the cytotoxicity in Figure 2 was because of apoptosis induced by delivering and expressing the Pdcd4 gene, the Annexin V-FITC and propidium iodide-labeling assay was performed. The FITC-labeled Annexin V binds to phosphatidylserine as a hallmark of early apoptosis, 31 resulting in Annexin V þ /PI À cells. In contrast, propidium iodide enters necrotic or late apoptotic cells and binds to cellular DNA, resulting in Annexin V þ /PI þ cells. 32 The Annexin V staining results (Figure 4) confirmed that the high cytotoxicity of F-PBac-Pdcd4 was due to apoptosis and that the level of apoptosis induced by treatment with F-P-Bac-Pdcd4 was much higher than that induced by Bac-Pdcd4 or P-BacPdcd4, indicating that the high transduction efficiency of F-P-Bac-Pdcd4 induced more apoptosis.
As expected from the in vitro study results, F-P-BacPdcd4 was proved to be a more efficient gene carrier for targeting tumors and inducing apoptosis in vivo than BacPdcd4 or P-Bac-Pdcd4. We constructed KB xenograft model mice for profiling the tumor growth after administration of F-P-Bac-Pdcd4 every 3 days. Many studies have been reported that drugs or genes were repeatedly treated every 2-7 days for tumor suppression in xenograft model mice because of the instability of drugs or genes. 18, 33 In a preliminary study, we repeatedly injected the F-P-Bac-Pdcd4 every 7 days because of the transient transcription of baculovirus in mammalian cells. 34 In this study, more tumor growth suppression was expected by administration of F-P-Bac-Pdcd4 every 3 days, resulting in 1.5 times more tumor growth suppression than administration every 7 days. Intratumor injection of F-P-Bac-Pdcd4 in tumor xenograft model mice resulted in a reduction in Bcl-2 expression and increase in Bcl-associated death promoter and BAX expression (Figure 7 ), indicating that tumor growth was retarded by apoptosis induced by expressing the PDCD4 protein (Figures 6 and 7) . Recently, it has been reported that the Bcl-2 family has an important regulatory role in apoptosis. 32 Bcl-2 is located mainly in the outer membranes of the mitochondria and has a role in preventing apoptosis by inhibiting the redistribution and release of cytochrome c into the cytoplasm. 15, 20 On the other hand, activation of Bcl-associated death promoter and BAX as pro-apoptotic proteins is known to induce apoptosis in cancer cells. The ratio between Bcl-2 and BAX protein can determine cell survival because anti-apoptotic family members such as Bcl-2 and Bcl-xL hold BAX and BAK in check, possibly by forming heterodimers with these molecules, and maintain the mitochondrial integrity to ensure survival. [35] [36] [37] Moreover, alterations in the profile of expression of Bcl-2 family members occur exclusively in cells that undergo apoptosis, which is generally associated with upregulation of BAX, with or without downregulation of the anti-apoptotic gene Bcl-2. 35 Our results showed that delivered F-P-Bac-Pdcd4 suppressed the expression of Bcl-2 protein, whereas Bcl-associated death promoter and BAX expression levels increased both in vitro and in vivo (Figures 6 and 7) . Together, these experiments suggest that the Pdcd4 gene delivered by F-PBac-Pdcd4 could efficiently facilitate apoptosis both in vitro and in vivo.
In conclusion, F-P-Bac-Pdcd4 was successfully prepared and its potential as a tumor-targeting gene delivery system was evaluated both in vitro and in vivo. Delivering the Pdcd4 gene, using F-P-Bac-Pdcd4 efficiently, induced apoptosis in KB cells. The expression level of PDCD4 protein, which depends on the transduction efficiency of the carrier, had a great impact on tumor growth. Our results suggest that F-P-Bac-Pdcd4 may have potential as an effective gene carrier with tumor specificity, thereby opening the possibility for novel cancer gene therapy.
